Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.

Future oncology (London, England) - 1 Dec 2008

Nemunaitis Jackie M, Nemunaitis John

Abstract excerpt

Li-Fraumeni syndrome is a rare autosomal dominant cancer predisposition syndrome. The majority of families fulfilling definition of Li-Fraumeni syndrome demonstrate inherited abnormalities involving the p53 gene. Cells with dysfunctional p53 are predisposed to the development of cancer phenotype. Advexin (Introgen Therapeutics Inc., TX, USA) is an adenoviral-based experimental therapeutic that provides delivery...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Genetic Therapy
Share to Li-Fraumeni Syndrome

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Tumor Suppressor Protein p53

Share to Viral Vaccines

Source

Identifiers

PMID: 19086841
DOI: 10.2217/14796694.4.6.759

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.PMID 19086841Read ↗

<i>p53</i> therapy in a patient with Li-Fraumeni syndromeSemantic proximity Read ↗

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Semantic proximity Read ↗

Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53Semantic proximity Read ↗

Head and neck cancer: Response to p53‐based therapeuticsSemantic proximity Read ↗

Adenovirus p53 gene therapySemantic proximity Read ↗

Li-Fraumeni Syndrome: An In-depth OverviewSemantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read ↗

Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.Semantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

[New knowledge of Li-Fraumeni syndrome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.